Climb Bio (CLYM) Capital Expenditures (2024 - 2025)
Climb Bio (CLYM) posted Capital Expenditures of $1.4 million for Q3 2025, up 2078.79% on a QoQ basis from $66000.0 in Q2 2025, and up 9686.67% year-over-year from $14693.5 in Q3 2024.
Climb Bio (CLYM) Capital Expenditures (2024 - 2025) Analysis & Trends
Climb Bio's Capital Expenditures history runs 2 years deep, the most recent figure standing at $1.4 million for Q3 2025.
- Quarterly Capital Expenditures rose 9686.67% year-over-year to $1.4 million in Q3 2025, while the trailing twelve-month figure through Mar 2026 was $1.5 million (up 616.19% YoY) and the FY2025 annual result came in at $1.5 million, up 657.0% from the prior year.
- Capital Expenditures was $1.4 million for Q3 2025 at Climb Bio, up from $66000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $1.4 million in Q3 2025 and bottomed at -$15000.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 43.25 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 786,000.00 |
| 10 | Climb Bio | 870.33 Mn | 870.33 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 1.44 Mn |
| Sep 30, 2025 | 1.44 Mn |
| Jun 30, 2025 | 66,000.00 |
| Jun 30, 2025 | 66,000.00 |
| Mar 31, 2025 | 10,000.00 |
| Mar 31, 2025 | 10,000.00 |
| Dec 31, 2024 | 215,000.00 |
| Dec 31, 2024 | 215,000.00 |
| Sep 30, 2024 | -15,000.00 |
| Sep 30, 2024 | -15,000.00 |